HC Wainwright Has Bearish Estimate for HRMY Q4 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at HC Wainwright cut their Q4 2026 earnings estimates for Harmony Biosciences in a research report issued to clients and investors on Monday, July 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.89 per share for the quarter, down from their previous forecast of $1.03. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.26 per share.

HRMY has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Tuesday, June 30th. Truist Financial increased their price target on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Weiss Ratings raised Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. Finally, Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Harmony Biosciences Trading Up 10.0%

Shares of NASDAQ:HRMY opened at $36.84 on Tuesday. The company has a 50 day moving average of $33.66 and a 200-day moving average of $32.64. The firm has a market cap of $2.13 billion, a P/E ratio of 14.85, a P/E/G ratio of 0.32 and a beta of 0.94. Harmony Biosciences has a twelve month low of $25.52 and a twelve month high of $40.87. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. During the same period in the previous year, the business posted $0.78 EPS. The firm’s quarterly revenue was up 16.6% on a year-over-year basis.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its position in shares of Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the period. Leonteq Securities AG acquired a new stake in Harmony Biosciences during the 4th quarter worth about $30,000. Allworth Financial LP lifted its stake in Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after buying an additional 602 shares in the last quarter. Clearstead Advisors LLC lifted its stake in Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after buying an additional 699 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in Harmony Biosciences during the fourth quarter valued at about $47,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.